Side effects of the BNT162b2 vaccine in the personnel of the Military Central Hospital.

OBJECTIVE: The pandemic disease by SARS-CoV-2 infection does not have an effective treatment. To prevent the disease, scientists developed vaccines that the clinicians use as an emergency licensed vaccine. The objective of this study was to determine the side effects in personnel vaccinated at the Military Central Hospital of Mexico with the BNT162b2 vaccine. PATIENTS AND METHODS: This study included the subjects who had received both doses of the BNT162b2 vaccine between December 2020 and February 2021. We asked about the side effects after the first and the second vaccine doses. One group had no history of COVID-19, and the second had a history of COVID-19. ANTI-SARS-CoV-2 antibodies were measured by the immunodetection technique in the second group only. RESULTS: We included 946 participants, 62% were women, and 80% were without comorbidities; 680 were included in the first group, and only 266 were in the second group. After the first dose, 77% of the first group and 86% of the second group presented some side effects. After the second dose, 84% of the first group and 89% of the second group showed some side effects. The main side effect was mild pain. All participants (126) were IgG positive, and only 26.9% were IgM positive at 17.5 days (12.8 days, 20.3 days) after the second dose. CONCLUSIONS: There is a positive correlation between side effects after the first dose in patients with a history of previous SARS-CoV-2 infection compared to those who did not. Nevertheless, this correlation is not present after the second dose. The low percentage of IgM could be related to the time interval between vaccination and sample measure.

ALBUMIN LEVELS HAVE STRONGASSOCIATION WITH MORTALITY IN COVID-19 INFECTED PATIENS

Introduction: To optimize hospital management of COVID-19 patients it is important to have parameters that allow us to identify patient with an increased risk of death. Although hypoalbuminemia has been related with severity in COVID-19, there is no agreement of the albumin cutoff points with a potential clinical use. Additionally, a measure of strength of the association between albumin levels and mortality has not been reported. Therefore, the aim of this study is to evaluate if Child Pug albumin categories are associated with mortality and obtain the strength of the association. Methods: Patients admitted to hospitalization with a positive SARS CoV 2 PCR from 4 April to 24 June 2020 were analyzed. Three groups were formed based on Child-Pugh albumin categories. Death frequency were compared between groups and statistical significance of the difference were assessed using a Xi2 test, strength of association between albumin levels and death was evaluated with a Kendall´s Tau B test. Results: A total of 348 patients were studied, age was 54.4 ± 14.7 years, 250 (71.8%) were male and 182 patients died (52%). Association of Albumin level and Death is presented Table 1, Kendall Tau B shows that knowing albumin level improves in 32% the prediction of death and since it has a negative coefficient at a lower level of albumin, risk of death increase. Conclusions: Kendall´s Tau-B shows a strong association between Child-Pug albumin categories and death, so is possible it´s use in clinical decisions as a marker of severity.